The French medical cannabis market is now in the very final stage of decision-making before being implemented nationally, as the
French authorities will present a first draft of the long-awaited pricing and reimbursement decree for medical cannabis on February 18,
Earlier this week (Tuesday, January 27), France’s government survived two no-confidence votes, finally passing its contentious 2026 budget following months
Thousands of French medical cannabis patients will continue to receive their treatment for the foreseeable future, as the highly anticipated
Augur Associates and Newsweed, two organisations at the forefront of the ongoing developments in the region, believe that the incoming system not only sidesteps many of the issues other countries have faced in the implementation phase, but that it could reestablish the country’s standing as a model of inspiration for neighbouring states and prospective forthcoming EU supra-regulation.
A number of countries in Europe are currently at some stage of medical cannabis reform. These reforms are set to lay the foundation for five permanent medical cannabis markets in the region.
In a press release published on 9 April, the Académie de Médecine (French Academy of Medicine) reiterated its prohibitionist stance on cannabis, citing a select range of public health concerns and international studies to support its position while consciously omitting the harm caused by prohibition.
France’s four-year campaign to launch a fully regulated generalised medical cannabis framework is finally being realised.
After years of waiting, France is set to take a key step towards authorising the production and dispensing of medical cannabis.
Thousands of French medical cannabis patients have been given a temporary reprieve, enabling them to continue accessing their treatment for another six months.
French patient associations have warned that medical cannabis patients could soon face a disruption in treatment as its long-running experiment
A proposal has been tabled in France aimed at further extending the country’s long-running medical cannabis ‘experiment’ to ensure patients
Reported by Newsweed.fr While the French National Agency for the Safety of Medicines (ANSM) assured at the beginning of the
Germany’s cannabis decriminalisation takes effect On April 1, 2024, Germany’s long-fought CanG bill came into effect, seeing thousands of supporters
The French National Medicines Safety Agency (ANSM) has confirmed that flowers will not be included in its upcoming generalised medical
2023 has been a milestone year for European cannabis. Europe’s first fully legal adult-use cannabis stores have opened in Switzerland.
Switzerland’s pilots begin sales Two of Switzerland’s adult-use cannabis pilot projects have entered their sales phase over the last week
Following months of uncertainty and doubt, thousands of medical cannabis patients in France can now breathe a sigh of relief
We won’t spam you
